Terms: = Leukemia AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
32 results:
1. Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c-KIT, and ret Anti-Targets.
Akwata D; Kempen AL; Dayal N; Brauer NR; Sintim HO
ChemMedChem; 2024 Jan; 19(1):e202300442. PubMed ID: 37971283
[TBL] [Abstract] [Full Text] [Related]
2. Ponatinib: An update on its drug targets, therapeutic potential and safety.
Gao Y; Ding Y; Tai XR; Zhang C; Wang D
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188949. PubMed ID: 37399979
[TBL] [Abstract] [Full Text] [Related]
3. PLM-101 is a novel and potent FLT3/ret inhibitor with less adverse effects in the treatment of acute myeloid leukemia.
Choi YJ; Park J; Choi H; Oh SJ; Park JH; Park M; Kim JW; Kim YG; Kim YC; Kim MJ; Kang KW
Biomed Pharmacother; 2023 Sep; 165():115066. PubMed ID: 37392657
[TBL] [Abstract] [Full Text] [Related]
4. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
5. Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.
Fu YH; Ou DL; Yang YR; Su KW; Chen CY; Tien HF; Lai ZS; Shen CJ; Chien HF; Lin LI
Cancer Gene Ther; 2022 Jun; 29(6):784-792. PubMed ID: 34117374
[TBL] [Abstract] [Full Text] [Related]
6. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a secondary
Pendrick DM; Oberg JA; Hsiao SJ; Chung WK; Koval C; Sireci A; Kuo JH; Satwani P; Glasser CL; Sulis ML; Mansukhani MM; Glade Bender JL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936199
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to leukemia Therapy.
Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
[TBL] [Abstract] [Full Text] [Related]
9. Role of ret protein-tyrosine kinase inhibitors in the treatment ret-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract] [Full Text] [Related]
10. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract] [Full Text] [Related]
11. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract] [Full Text] [Related]
12. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract] [Full Text] [Related]
13. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.
Alemán JO; Farooki A; Girotra M
Endocr Relat Cancer; 2014 Jun; 21(3):R247-59. PubMed ID: 24478055
[TBL] [Abstract] [Full Text] [Related]
14. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant ret kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract] [Full Text] [Related]
15. Progress in Pediatrics in 2012: choices in allergy, endocrinology, gastroenterology, hematology, infectious diseases, neurology, nutrition and respiratory tract illnesses.
Caffarelli C; Santamaria F; Vottero A; Bernasconi S
Ital J Pediatr; 2013 May; 39():26. PubMed ID: 23651601
[TBL] [Abstract] [Full Text] [Related]
16. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic ret mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract] [Full Text] [Related]
17. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting ret proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract] [Full Text] [Related]
18. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract] [Full Text] [Related]
19. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.
Krust B; El Khoury D; Nondier I; Soundaramourty C; Hovanessian AG
BMC Cancer; 2011 Aug; 11():333. PubMed ID: 21812966
[TBL] [Abstract] [Full Text] [Related]
20. Fusion gene microarray reveals cancer type-specificity among fusion genes.
Løvf M; Thomassen GO; Bakken AC; Celestino R; Fioretos T; Lind GE; Lothe RA; Skotheim RI
Genes Chromosomes Cancer; 2011 May; 50(5):348-57. PubMed ID: 21305644
[TBL] [Abstract] [Full Text] [Related]
[Next]
